Bayer/GSK Levitra EU approval
Bayer/GlaxoSmithKline's erectile dysfunction therapy Levitra (vardenafil) receives marketing authorization in Europe, firms announce March 7. Approval of the PDE-5 inhibitor is based on clinical studies in 3,750 men. The Summary of Product Characteristics states that Levitra allows some men to attain an erection as early as 15 min. after dosing (25 min. for most men) and for up to nearly five hours after dosing, the firms say. The recommended starting dose of Levitra is 10 mg 25 to 60 min. before sexual activity. Vardenafil received a positive opinion from the European Committee for Proprietary Medicinal Products Nov. 21, 2002 (Pharmaceutical Approvals Monthly, Dec. 1, 2002, In Brief). Lilly ICOS' Cialis (tadalafil) beat Levitra to market with its Nov. 12, 2002 EU approval (see related story, p. 3). Tadalafil and vardenafil are both currently "approvable" at FDA, pending submission of additional short-term clinical pharmacology studies for each ED agen
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
Calley Means defended reductions in force at the Health and Human Services Department that shocked and outraged federal workers and stakeholders.
Some employees were not impressed with FDA Commissioner Martin Makary's first speech to the agency staff, saying he did not seem to understand the agency's mission.
The loss of policy analyst, legal, project manager and social scientist positions has experts wondering if the Trump Administration is eyeing a broader effort to limit DTC advertising. The OPDP layoffs are expected to result in delayed reviews of promotional pieces.